![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach:
Dokumententyp
| Veröffentlichungsdatum
Springe zu: Zeitschriftenartikel
Anzahl der Publikationen: 8
Zeitschriftenartikel
Dreyling, M.; Morschhauser, F.; Bouabdallah, K.; Bron, D.; Cunningham, D.; Assouline, S. E.; Verhoef, G.; Linton, K.; Thieblemont, C.; Vitolo, U.; Hiemeyer, F.; Giurescu, M.; Garcia-Vargas, J.; Gorbatchevsky, I.; Liu, L.; Koechert, K.; Pena, C.; Neves, M.; Childs, B. H. und Zinzani, P. L.
(2017):
Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma.
In: Annals of Oncology, Bd. 28, Nr. 9: S. 2169-2178
Provencio Pulla, M.; Santoro, A.; Mollica, L.; Leppa, S.; Follows, G.; Lenz, G.; Kim, W. S.; Nagler, A.; Panayiotidis, P.; Demeter, J.; Ozcan, M.; Kosinova, M.; Bouabdallah, K.; Morschhauser, F.; Ishida, T.; Huang, L.; Garcia-Vargas, J.; Childs, B. H.; Zinzani, P. L. und Dreyling, M.
(2017):
Copanlisib treatment in patients with relapsed or refractory indolent B-cell lymphoma: Subgroup analyses from the CHRONOS-1 study.
In: Annals of Oncology, Bd. 28
Zinzani, P. L.; Santoro, A.; Leppa, S.; Demeter, J.; Follows, G. A.; Lenz, G.; Kim, W. S.; Mollica, L.; Nagler, A.; Diong, C. P.; Provenciio, M.; Stevens, D. A.; Trevarthen, D.; Maagnoli, M.; Cupit, L.; Yin, S.; Hiemeyer, F.; Garcia-Vargas, J.; Childs, B. H. und Dreyling, M.
(2017):
Efficacy and safety of Copanlisib in patients with relapsed/refractory follicular lymphoma: a subset analysis of the Chronos-1 study.
In: Haematologica, Bd. 102: S. 314-315
Dreyling, M.; Santoro, A.; Mollica, L.; Leppa, S.; Follows, G. A.; Lenz, G.; Kim, W. S.; Nagler, A.; Panayiotidis, P.; Demeter, J.; Ozcan, M.; Kosinova, M.; Bouabdallah, K.; Morschhauser, F.; Stevens, D. A.; Trevarthen, D.; Giurescu, M.; Kupit, L.; Childs, B. H. und Zinzani, P. L.
(2017):
Copanlisib (COP) in patients with relapsed or refractory indolent B-cell lymphoma: primary results of the pivotal Chronos-1 study.
In: Oncology Research and Treatment, Bd. 40: S. 12
Maddocks, K.; Gonzalez Barca, E.; Jurczak, W.; Liberati, A. M.; Duell, J.; Nagy, Z.; Papaj-K, T.; Andre, M.; Kalakonda, N.; Dreyling, M.; Zinzani, P. L.; Ambarkhane, S.; Weirather, J. und Salles, G.
(2017):
L-Mind: MOR208 Combined with Lenalidomide (Len) In Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R-R Dlbcl)-A Single-Arm Phase II Study.
In: Haematologica, Bd. 102: S. 174
Duell, J.; Gonzalez Barca, E.; Liberati, A. M.; Salles, G.; Gaidano, G.; Jurczak, W.; Nagy, Z.; Papajlk, T.; Andre, M.; Zinzani, P. L.; Kalakonda, N.; Ambarkhane, S.; Weirather, J.; Maddocks, K. und Dreyling, M.
(2017):
L-MIND: MOR208 combined with lenalidomide (LEN) in patients with relapsed or refractory diffuse large B-cell lymphoma (R-R DLBCL) - a single-arm phase II study.
In: Oncology Research and Treatment, Bd. 40: S. 68
Dreyling, M. H.; Morschhauser, F.; Bouabdallah, K.; Cunningham, D.; Bron, D.; Linton, K.; Assouline, S.; Verhoef, G.; Thieblemont, C.; Vitolo, U.; Garcia-Vargas, J.; Gorbatchevsky, I; Neves, M.; Grunert, J.; Hiemeyer, F.; Childs, B. H. und Zinzani, P. L.
(2016):
Phase 2a study of the phosphatidylinositol-3-kinase (PI3K) inhibitor copanlisib in patients with relapsed/refractory, indolent or aggressive lymphoma.
In: Oncology Research and Treatment, Bd. 39: S. 310
Dreyling, M.; Morschhauser, F.; Bouabdallah, K.; Cunningham, D.; Bron, D.; Linton, K.; Assouline, S.; Verhoef, G.; Thieblemont, C.; Vitolo, U.; Garcia-Vargas, J.; Gorbatchevsky, I.; Neves, M.; Grunert, J.; Hiemeyer, F.; Childs, B. H. und Zinzani, P. L.
(2016):
Phase 2a study of the Phosphatidylinositol-3-Kinase (PI3K) inhibitor Copanlisib in patients with relapsed/refractory, indolent or aggressive lymphoma.
In: Haematologica, Bd. 101: S. 104